Apple submitted a software workaround that could let the company sell non-infringing Apple Watch versions as soon as January 12, while appealing the US ITC ban
The Cupertino, Calif.-based tech giant won a temporary reprieve from a federal appeals court Wednesday, two months …
Context & Ripple Effects
Apple had already been reported to be pursuing a software-based route around the blood-oxygen patent dispute, and the appeals court then granted a temporary pause on the import ban. That combination gave Apple time to test whether a modified product could remain on sale while the underlying case moved forward.
The workaround turns an exclusion-order fight into a technical compliance question. Later, the ITC’s opposition to keeping the sales pause in place underscored that interim access to the US market remained contested even as Apple pursued its appeal.
First-order effects
- Apple could resume US sales of modified Apple Watch versions if the ITC accepts the software change as non-infringing, rather than waiting for the appeal to conclude.
- Masimo’s import remedy faces an immediate practical constraint: it must still cover the modified watches for the sales interruption to continue.
Second-order effects
- The dispute shifts attention from the existence of an import ban to whether a software-disabled or altered feature falls outside the asserted patents, raising the importance of technical review in the litigation.
- Apple’s retail and product teams gain a potential path to preserve availability, but may have to manage different feature configurations while the legal status remains unresolved.
Third-order effects
- If software changes repeatedly blunt hardware-related exclusion orders, wearable-device makers may increasingly design contested features to be separable through updates rather than fixed product changes.
- Patent remedies for connected devices could become more iterative: courts and agencies would be asked not only whether an original product infringes, but whether successive software variants do.
The trend: Connected-device patent disputes are increasingly testing whether software-configurable features can preserve market access while product-level remedies are appealed.